Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC

Xencor Inc

XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
Plamotamab (CD20xCD3) Phase 1b/2a in multi-drug resistant RA to begin H1 2025.
XmAb657 (CD19xCD3) Phase 1 in autoimmune disease starts H2 2025; preclinical B-cell depletion >99.98%.
XmAb819 (ENPP3xCD3) shows RECIST responses in ccRCC; dose escalation continues, target dose by YE 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.